Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Compass Therapeutics, Inc. (CMPX : NSDQ)

• Company Description    Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $2.07 Daily Weekly Monthly 20 Day Moving Average: 17,161,906 shares Shares Outstanding: 180.09 (millions) Market Capitalization: $372.78 (millions) Beta: 0.79 52 Week High: $6.88 52 Week Low: $1.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -60.27% -62.21% 12 Week -64.19% -66.89% Year To Date -61.45% -66.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 80 GUEST STREET SUITE 601 - BOSTON,MA 02135 USA ph: 617-500-8099 fax: - ir@compasstherapeutics.com http://www.compasstherapeutics.com

• General Corporate Information    Officers Thomas J. Schuetz - Chief Executive Officer Carl L. Gordon - Chairman Barry Shin - Chief Financial Officer Neil Lerner - Chief Accounting Officer Phil Ferneau - Director Peer Information Compass Therapeutics, Inc. (CORR.) Compass Therapeutics, Inc. (RSPI) Compass Therapeutics, Inc. (CGXP) Compass Therapeutics, Inc. (BGEN) Compass Therapeutics, Inc. (GTBP) Compass Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 20454B104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 180.09 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $372.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.00 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 16.67% vs. Previous Quarter: -11.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -39.75 12/31/25 - -43.61 09/30/25 - -48.89 ROA 03/31/26 - -35.29 12/31/25 - -38.05 09/30/25 - -42.47 Current Ratio 03/31/26 - 19.04 12/31/25 - 15.02 09/30/25 - 17.82 Quick Ratio 03/31/26 - 19.04 12/31/25 - 15.02 09/30/25 - 17.82 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.04 12/31/25 - 1.11 09/30/25 - 1.18 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©